A型肉毒毒素注射在改善面上部动力性皱纹的疗效及可行性分析

目的:探讨A型肉毒毒素改善面上部动力性皱纹的临床疗效,并分析其可行性。方法:选择2016年2月到2016年10月在我院接受面上部动力性皱纹改善治疗的患者35例作为研究对象,所有患者均给予注射A型肉毒毒素治疗。评价并比较患者在治疗后30 min、治疗后3 d、治疗后7 d的优良率。采用面部皱纹量表(FWS)评价患者面部皱纹严重程度指数,比较患者治疗前、治疗后4周及治疗后6月的FWS指数。观察并比较治疗后面上部紧绷感、乏力感、注射点局部瘀斑等不良反应发生情况。结果:患者治疗后30 min、3 d及7 d时的优良率逐渐升高,治疗后3 d、7 d的优良率明显高于治疗后30 min,治疗后7 d的优良率明显高于治疗后3 d,差异均具有统计学意义(P0.05)。患者治疗后4周和治疗后6月的FWS指数均明显小于治疗前,并且治疗后4周的FWS指数明显小于治疗后6月,差异均具有统计学意义(P0.05)。治疗后,仅有4例患者出现轻微不适,所有症状均于休息3-4 d后自行消失,不影响患者的正常工作和生活。结论:A型肉毒毒素改善面上部动力性皱纹的临床疗效显著,维持时间较长,不良反应较少且较轻,安全性较好,值得在临床上推广应用。     

A 型肉毒毒素治疗半侧面肌痉挛的临床疗效评价

目的：观察A型肉毒毒素对面肌痉挛患者的痉挛程度、抑郁症状和焦虑症状的改善。方法：对58例面肌痉挛患者进行局部注射A型肉毒毒素。在治疗前后对痉挛程度改善情况进行评定以及用汉密顿焦虑量表（HAMA）、汉密顿抑郁量表（HAMD）对焦虑状态、抑郁状态进行评分,并对药物的副作用进行观察。结果：A型肉毒毒素明显改善面肌痉挛患者的痉挛程度,治疗后2周的HAMA、HA肋评分较治疗前明显下降,且差异具有统计学意义（P〈0．01）。结论：局部注射A型肉毒毒素可迅速缓解或消除面肌痉挛患者肌肉痉挛及相关的抑郁和焦虑状态,提高患者的生活质量。     

A型肉毒毒素联合眼袋整形术对眼周皮肤松弛患者的疗效观察

目的:探讨A型肉毒毒素联合眼袋整形术对眼周皮肤松弛患者的治疗效果和对患者满意度的影响,为临床提供参考。方法:选取2015年6月至2016年6月间因眼周皮肤松弛来我院治疗的患者60例。患者根据自身意愿选择治疗方式,按其选择的治疗方式分组为对照组(n=28)和治疗组(n=32)。对照组采用单纯眼袋整形术进行治疗,治疗组采用A型肉毒毒素联合眼袋整形术治疗。治疗后对两组患者均随访6个月。观察记录患者手术后鱼尾纹的改善效果、眼袋减轻的情况和眼周皮肤光泽的改善效果。观察患者并发症的发生情况。随访结束时采用自制的满意度调查问卷对患者满意度进行调查。结果:经过治疗,治疗组鱼尾纹改善率为100.00%,明显高于对照组的60.71%;治疗组眼袋改善率为96.88%,明显高于对照组的32.14%;治疗组皮肤光泽改善率为87.50%,明显高于对照组的53.57%,差异均具有统计学意义(均P0.05)。治疗后,两组患者切口红肿、少量分泌物、小血肿的发生率比较无明显差异(P0.05),治疗组术眼红肿与外眦部切口瘀痕发生率明显少于对照组(P0.05)。治疗组总满意率为93.75%(30/32),明显高于对照组的67.86%(19/28),差异具有统计学意义(P0.05)。结论:A型肉毒毒素与眼袋整形术联合应用在眼周皮肤松弛的治疗上有较好的疗效和安全性,能明显降低患者术眼红肿与外眦部切口瘀痕的发生,并提高患者满意率,值得在临床上推广应用。     

超声引导下A型肉毒毒素注射治疗梨状肌综合征的疗效

目的探讨超声引导下A型肉毒毒素注射治疗梨状肌综合征的疗效。方法对我院康复医学科或骨科门诊诊断为梨状肌综合征的20例患者,按随机数字表法分为观察组和对照组各10例,观察组给予注射A型肉毒毒素治疗,对照组给予注射曲安奈德治疗。两组患者均在超声引导下进行药物注射,采用视觉模拟疼痛评分(visual analog scale,VAS)量表、李氏髋关节功能评分标准对两组患者治疗前和治疗后6个月的评分进行评定,并比较两组效果。结果治疗前,两组患者的VAS评分及李氏髋关节功能评分比较,差异无统计学意义(P0.05)。治疗6个月后,两组患者的VAS评分均较治疗前降低,李氏髋关节功能评分均较治疗前提高,且观察组各指标改善均优于对照组,差异均有统计学意义(均P0.05)。结论 A型肉毒毒素注射治疗梨状肌综合征患者的效果优于曲安奈德,为今后梨状肌综合征患者的临床治疗提供一定的指导意义。     

CO2点阵激光联合湿润烧伤膏对创伤性瘢痕的疗效分析

目的:探讨CO_2点阵激光联合湿润烧伤膏治疗创伤性瘢痕的临床疗效。方法:选取73例创伤性瘢痕患者,年龄21-35岁,对照组(35例)给予CO_2点阵激光术治疗,术后涂抹莫匹罗星软膏护理,观察组(38例)采用CO_2点阵激光术联合湿润烧伤膏治疗。通过对患者治疗后3个月的体征、疗效及3个月内不良反应的发生情况评价CO_2点阵激光术联合湿润烧伤膏对创伤性瘢痕的疗效。结果:与治疗前相比,两组治疗后3个月的VSS评分均明显提高(P0.05),但两组间VSS评分相比差异没有统计学意义(P0.05)。治疗后3个月,观察组的治疗有效率明显高于对照组(P0.05),治疗后3个月期间,观察组的不良反应发生率明显低于对照组(P0.05),色素沉积和创面感染是主要的不良反应症状。结论:CO_2点阵激光技术联合润湿烧伤膏对于创伤性瘢痕具有良好的治疗效果,且安全性高。     

A型肉毒毒素耳后注射治疗帕金森病合并神经性耳鸣患者的疗效探讨

摘要 目的：探讨A型肉毒毒素耳后注射治疗帕金森病合并神经性耳鸣患者的疗效。方法：收集2016年3月至2021年6月苏州大学附属第二医院耳鼻喉科或神经内科门诊就诊或住院的帕金森病患者,追问病史,发现部分患者有单侧或双侧耳鸣症状,并进行电测听+声导抗检查回报,其中有73 %患者有神经性听力下降,根据治疗方法将其分为A型肉毒毒素耳后注射组（实验组,22例）和地塞米松耳后注射组（对照组,22例）,A型肉毒毒素注射组予以100U A型肉毒毒素耳垂后方自上而下3个点注射,地塞米松注射组予以5 mg地塞米松耳垂后方自上而下3个点注射,对比两组鸣残疾评估量表（THI）评分、耳鸣评价量表（TEQ）评分、治疗总有效率、汉密尔顿焦虑量表（HAMA）和汉密尔顿抑郁量表（HAMD）评分、匹兹堡睡眠质量指数（PSQI）评分。结果：两组治疗前THI和TEQ评分比较无差异（P>0.05）,两组治疗后THI和TEQ评分均有所降低,且实验组均低于对照组（P<0.05）;实验组治疗后1周、治疗后4周、治疗后14周治疗总有效率为63.64 %、81.82 %、90.91 %,对照组治疗总有效率分别为63.64 %、63.64 %、72.73 %,两组治疗总有效率比较无差异（P>0.05）,但实验组略高于对照组;两组治疗前HAMA、HAMD评分比较无差异（P>0.05）,两组治疗后14周HAMA、HAMD评分均有多下降,且实验组均低于对照组（P<0.05）;两组治疗前入睡时间、睡眠时间、睡眠质量、睡眠效率、睡眠障碍、日间功能障碍、安眠药物评分以及总分比较无差异（P>0.05）,两组治疗后14周上述各项评分均有所降低,且实验组均低于对照组（P<0.05）。结论：A型肉毒毒素耳后注射治疗帕金森病合并神经性耳鸣患者,可改善耳鸣症状,提高临床治疗效果,缓解焦虑抑郁情绪,改善睡眠质量,值得临床不断深入研究。     

可美容的剧毒物--肉毒毒素

目前 ,一种被誉为“毒死皱纹”的毒针美容法正在风靡全球。这种奇妙的毒针是何物呢 ?是 A型肉毒毒素(botulinumtoxin,英文缩写为 BOTOX)。A型肉毒毒素 ,是世界上最毒的物质之一 ,一次注射过量足以致人死命 ;但如果将 0 .1m L 的肉毒毒素注射进皮肤 ,这个部位的皱纹竟会消失 6个月。A型肉毒毒素为什么能够消除皱纹呢 ?要解释这个问题 ,须要先了解皱纹形成的生理原因 :人体骨骼肌的运动依赖于运动神经的兴奋传递 ,这种兴奋传递来自于运动神经末梢释放的化学物质——乙酰胆碱的刺激 ,乙酰胆碱通过突触结构可刺激肌肉并使其收缩 ,从而产生了…     

A型肉毒毒素联合肌电生物反馈治疗脑卒中后上肢肌痉挛的临床疗效分析

目的:分析A型肉毒毒素与肌电生物反馈联合用于治疗脑卒中后上肢肌痉挛的临床疗效。方法:选择2014年10月至2016年12月辽宁本溪市中心医院和北京博爱医院收治的84例脑卒中后上肢肌痉挛患者,并将其随机分为观察组和对照组,每组42例。两组患者均首先接受常规康复训练,随后对照组加用肌电生物反馈治疗,观察组患者在对照组的基础之上注射A型肉毒毒素。采用改良Ashworth痉挛量表(MAS)比较两组治疗前后的上肢肌痉挛改善情况,采用Fugl-Meyer评定量表评价患者上肢运动功能,采用量角器测量治疗前后患者的腕关节主动活动范围,采用改良的Barthel指数评价患者治疗前后的日常生活能力。结果:治疗后,观察组的上肢痉挛改善总有效率显著高于对照组(P0.05);治疗2周和4周时,两组的Fugl-Meyer评分、腕关节主动活动范围、改良的Barthel指数(MBI)均较治疗前显著升高(P0.05),且观察组治疗后2周和4周的Fugl-Meyer评分、腕关节主动活动范围、改良的Barthel指数(MBI)均显著高于对照组(P0.05)。结论:A型肉毒毒素与肌电生物反馈联合用于治疗脑卒中后上肢肌痉挛的临床疗效显著,可有效降低患者上肢痉挛状态,改善上肢和腕部运动能力,提高患者的日常生活能力。     

不同能量CO2点阵激光对博来霉素诱导的小鼠增生性瘢痕的作用及Hedgehog信号通路的影响

目的:探讨不同能量CO_2点阵激光对博莱霉素诱导的小鼠增生性瘢痕模型的作用及其对瘢痕组织中Hedgehog信号通路的影响。方法:于雄性C57BL/6J小鼠背部皮肤注射博来霉素(1 mg/d,4周)制作增生性瘢痕模型,另取4只小鼠背部注射PBS缓冲液作为对照。造模成功之后,随机将小鼠分为瘢痕对照组(模型组),10 mj激光治疗组(10 mj组)和20 mj激光治疗组(20 mj组),每组6只小鼠。10 mj组小鼠给予10 mj激光治疗(共3次,每次间隔2周);20 mj组小鼠给予20 mj激光治疗(共3次,每次间隔2周)。治疗结束后,处死小鼠,取瘢痕全层标本进行病理组织学染色观察(HE、Masson染色)以及α-平滑肌肌动蛋白(α-SMA)、GLi1免疫荧光观察。结果:①我们成功复制出小鼠增生性瘢痕模型;②20 mj CO_2点阵激光治疗可有效修复瘢痕组织,经治疗后皮肤瘢痕程度显著减轻,同时可降低真皮层厚度和减轻瘢痕组织的纤维化程度;③免疫荧光染色结果提示,CO_2点阵激光可显著减少小鼠皮肤增生性瘢痕中α-SMA、GLi1表达。结论:于小鼠的背部皮肤注射博莱霉素可建立增生性瘢痕模型。CO_2点阵激光为治疗增生性瘢一种有效的治疗方式,其作用可能与其对Hedgehog信号通路的抑制有关。     

A型肉毒毒素不同注射方式治疗单纯性咬肌肥大患者的疗效及对咬肌厚度的影响

摘要 目的：探讨A型肉毒毒素不同注射方式治疗单纯性咬肌肥大患者的疗效及对咬肌厚度的影响。方法：选择2014年6月-2016年6月在我院接受治疗的单纯性咬肌肥大患者84例,根据随机数字表法将患者均分为研究组和对照组,两组各42例,其中对照组进行单次注射A型肉毒毒素,研究组给予连续注射A型肉毒毒素。所有患者在治疗前、治疗后1个月、治疗后3个月、治疗后6个月、治疗后9个月、治疗后12个月,采用超声对进行咬肌厚度进行检测;在治疗后12个月调查两组患者对治疗效果的主观评价,同时邀请两名专家对患者的治疗效果进行评价。记录患者在治疗后出现的不良反应。结果：研究组在治疗后9个月、治疗后12个月的咬肌厚度显著低于对照组,差异有统计学意义（P<0.05）,对照组患者的咬肌厚度在治疗后1个月至治疗后6个月逐渐降低,治疗后6个月达到最低值,在治疗后9个月和治疗后12个月开始回升。研究组患者的咬肌厚度在治疗后一直呈下降的趋势,并在治疗后12个月达到最低值。两组治疗后的各个时间点的咬肌厚度均低于治疗前,差异有统计学意义（P<0.05）。研究组患者本人的主观评价和专家评价为A、B、C的比例均显著低于对照组,D、E的比例均显著高于对照组,差异有统计学意义（P<0.05）。两组患者不良反应发生情况无统计学差异（P>0.05）。结论：与单次注射相比,A型肉毒毒素连续注射能更好的降低咬肌厚度,同时患者对治疗效果的主观评价和专家的评价较好,且不良反应少,临床上治疗咬肌肥大时可选用连续注射A型肉毒毒素的方式。     

New indications for botulinum toxin type a in cosmetics: mouth and neck

Botulinum toxin type A is frequently used to smooth hyperkinetic lines in the periocular and forehead areas of the upper face, but it has been used less frequently for indications in the lower face and neck. This study was designed to determine whether botulinum toxin treatment of the mouth and neck areas is as clinically successful as the treatment of the upper face. This was a retrospective study of patients who were treated with botulinum toxin type A (Botox) to soften hyperkinetic facial wrinkles. Of 100 patients randomly selected from a single clinical practice, 91 met the inclusion criteria and were divided into two groups for analysis. The 56 patients in group 1 did not receive treatment in the mouth and neck areas, whereas the 35 patients in group 2 were treated at least once in the mouth and neck areas. Patients were surveyed for periods ranging from 7 to 49 months. Most patients in each group had a single botulinum procedure during this period. Both groups of patients had comparable improvement of wrinkles both at the evaluation immediately after the neuromuscular blockade and during follow-up. In comparison with patients whose treatment was confined to the upper face, patients who received global treatment with botulinum toxin type A, including injections in the mouth and neck areas, were injected in more sites per procedure and had more procedures in combination with other therapies. Patient satisfaction with botulinum toxin treatment and outcomes was high in both groups. Botulinum toxin type A is an important tool within the therapeutic spectrum for the treatment of hyperkinetic facial wrinkles, including those in the areas of the mouth and neck.     

A型肉毒素与复方倍他米松注射液联用治疗瘢痕疙瘩患者的疗效及安全性研究

目的:分析A型肉毒素与复方倍他米松注射液联用治疗瘢痕疙瘩患者的疗效及安全性。方法:选取2015年1月-2016年8月期间我院收治的90例瘢痕疙瘩患者为研究对象,根据治疗方法将患者随机分为A组、B组和C组各30例。A组给予A型肉毒素治疗,B组给予复方倍他米松注射液治疗,C组给予A型肉毒素联合复方倍他米松注射液治疗。比较三组患者的相关指标改善评分、临床疗效、不良反应发生率和复发率。结果:C组患者体积、痛痒觉、硬度和自我评价的改善评分均高于B组和A组(P0.05),B组的各项指标改善评分和A组相比差异无统计学意义(P0.05)。三组总有效率比较差异有统计学意义,且C组高于B组(P0.05),A组和C组总有效率比较差异无统计学意义(P0.05)。A组不良反应总发生率低于B组和C组,差异有统计学意义(P0.05),B组与C组不良反应总发生率相比,差异无统计学意义(P0.05)。A组和C组治疗后半年、1年瘢痕疙瘩复发率均低于B组(P0.05),但A组和C组比较差异无统计学意义(P0.05)。结论:与单独使用A型肉毒素或复方倍他米松注射液相比,A型肉毒素与复方倍他米松注射液联合使用治疗瘢痕疙瘩能显著提高疗效,降低复发率,且不会增加不良反应发生率,安全性较高,值得进一步推广应用。     

Double-blind,placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines

The objective of this study was to evaluate the efficacy and safety of botulinum toxin type A for the treatment of glabellar lines. Patients with moderate or severe glabellar lines at maximal frown received intramuscular injections of placebo or 20 U of botulinum toxin type A (Botox; Allergan, Inc., Irvine, Calif.) distributed among five injection sites (one in the procerus muscle and two in each corrugator supercilii). Follow-up assessments were performed at 7, 30, 60, 90, and 120 days after injections. Efficacy measures were the physician's rating of glabellar line severity at maximal frown and at rest (none, mild, moderate, or severe) and the patient's global assessment of changes in glabellar lines, from +4 (100 percent better) to -4 (100 percent worse). A total of 273 patients were enrolled (botulinum toxin, 202 patients; placebo, 71 patients). All except five patients (botulinum toxin, two patients; placebo, three patients) completed the study. For the physician's rating at maximal frown, the responder rate (percentage of patients with severity ratings of none or mild in follow-up evaluations) for the botulinum toxin group peaked at 77 percent at day 30 and was significantly greater than that for the placebo group at every follow-up visit (p < 0.001). For the patient's assessment, the responder rate (percentage of patients with scores of +2 or more) for the botulinum toxin group peaked at 89 percent at day 30 and was significantly greater than that for the placebo group at every follow-up visit (p < 0.001). Rates of adverse events were similar for the two groups. The only adverse event with an incidence of >/=5 percent was headache (botulinum toxin, 11 percent; placebo, 20 percent). The incidence of blepharoptosis was 1 percent for the botulinum toxin group. Botulinum toxin type A was remarkably safe and effective in reducing glabellar lines.     

CO2 激光联合胸腺五肽治疗尖锐湿疣的临床效果分析

目的:探讨CO2激光联合胸腺五肽治疗尖锐湿疣的临床疗效。方法:将我院2010年2月-2011年8月期间收治的82例尖锐湿疣患者随机分为两组,治疗组50例采用CO2激光器治疗联合胸腺五肽肌注;对照组32例单纯采用CO2激光器治疗;两组治疗疗程结束后观察临床疗效。结果:治疗组50例,一次治愈者46例,占92%;二次治愈者4例,占8%。对照组32例,一次治愈者19例,占59.4%;二次治愈者13例,占40.6%。两组一次治愈率比较差异明显,具有统计学意义(P<0.05)。两组术后局部轻度水肿和疼痛,无需处理1~3天缓解或痊愈。结论:CO2激光联合胸腺五肽治疗尖锐湿疣临床疗效好,并具有治疗简便,术后不良反应少,治愈率高等特点。     

CO_2激光联合胸腺五肽治疗尖锐湿疣的临床效果分析

目的：探讨CO2激光联合胸腺五肽治疗尖锐湿疣的临床疗效。方法：将我院2010年2月-2011年8月期间收治的82例尖锐湿疣患者随机分为两组,治疗组50例采用CO2激光器治疗联合胸腺五肽肌注;对照组32例单纯采用CO2激光器治疗;两组治疗疗程结束后观察临床疗效。结果：治疗组50例,一次治愈者46例,占92%;二次治愈者4例,占8%。对照组32例,一次治愈者19例,占59.4%;二次治愈者13例,占40.6%。两组一次治愈率比较差异明显,具有统计学意义（P〈0.05）。两组术后局部轻度水肿和疼痛,无需处理1~3天缓解或痊愈。结论：CO2激光联合胸腺五肽治疗尖锐湿疣临床疗效好,并具有治疗简便,术后不良反应少,治愈率高等特点。     

Efficacy of reconstituted and stored botulinum toxin type A: an electrophysiologic and visual study in the auricular muscle of the rabbit

Once botulinum toxin type A is reconstituted, the manufacturer recommends that it be used in approximately 4 hours. As a result, a significant amount of this costly drug is often discarded because it is not completely used in the recommended period. The purpose of the present study was to compare fresh versus stored reconstituted botulinum toxin type A for (1) initial potency, (2) duration of action, and (3) bacterial colonization.Using a rabbit model, 20 New Zealand White rabbits were divided into four groups (I to IV). All rabbits had an injection of 2.5 U of reconstituted botulinum toxin into the right anterior auricular muscle. The first group was injected with botulinum toxin type A that was freshly reconstituted and served as the control. The second, third, and fourth groups were injected with botulinum toxin type A that had been reconstituted and stored for 2, 6, and 12 weeks, respectively, in a conventional freezer. Each rabbit had daily visual evaluation of the ear, with the position of auricle being graded from I to III. In addition, each rabbit had a nerve conduction study performed on the right anterior auricular muscle before injection and every 2 weeks after injection. Amplitude was chosen as the principal variable in the data analysis because it is the best predictor of physiologic changes at the muscle motor unit level. The endpoint of the study was defined as the time at which the nerve conduction studies and the visual inspections returned to baseline, preinjection levels. Botulinum toxin type A was also cultured before injection into each group.Overall, the nerve conduction data revealed a trend with a faster recovery (return to baseline) with the stored botulinum toxin. Groups IV and III returned to baseline first, followed by groups II and I. However, there was no significant difference among the groups at 2 and 4 weeks after injection, indicating that initial potency was unchanged. The differences between the groups became significant (p < 0.05) at 6 weeks and onward, suggesting that the duration was affected. Group I (fresh botulinum toxin) and group II (toxin stored for 2 weeks) had comparable outcomes and were not significantly different at any time period. Under visual inspection, the mean recovery time for each group was as follows: group IV, 5.4 weeks; group III, 7.0 weeks; group II, 6.75 weeks; and group I, 7.80 weeks. The results showed significance (p < 0.05) beginning after 3 weeks among some groups. Again, there was an overall quicker trend to return to baseline with the longer storage of the botulinum toxin (groups III and IV). These results support the authors' conduction study data, which suggest that the initial potency is not affected but the duration of action is. Again, groups I and II had comparable results. Microbiology cultures showed no growth of either aerobic or anaerobic bacteria at 7 days.In conclusion, using the rabbit model, it seems that reconstituted and stored botulinum toxin type A has the same initial potency but the duration of action is affected sometime after 2 weeks of storage. No bacterial contamination was associated with storing unpreserved reconstituted botulinum toxin type A for up to 12 weeks.     

Temporary management of upper lid ptosis, lid malposition, and eyelid fissure asymmetry with botulinum toxin type A

During the past 10 years the primary focus for the aesthetic use of botulinum toxin has been directed to the treatment of dynamic facial lines. This agent has been shown to be very effective for the improvement of facial shape. The use of botulinum toxin type A for the correction of a variety of presentations of facial asymmetry has also been well established. The general principles regarding the counter-effects of facial muscle protagonists and antagonists and their potential effects on the position of facial soft-tissue regions apply here as well. Twenty-two patients received botulinum toxin type A for the temporary treatment of mild to moderate unilateral upper eyelid ptosis and aesthetic improvement of lower eyelid position, with favorable results. Although commonly related to a rare yet feared adverse consequence from the inappropriate application of botulinum toxin, its application for the treatment of upper eyelid ptosis, eyelid position, and other lid fissure asymmetries for aesthetic improvement is presented.